Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-30
1997-11-25
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3152
Patent
active
056913435
ABSTRACT:
A method is provided to treat inflammatory bowel disease by topically administering to the colon an effective amount of azathioprine or a pharmaceutically acceptable salt thereof, preferably via formulations adapted for delayed-release oral or rectal administration.
REFERENCES:
patent: 3056785 (1962-10-01), Hitchings et al.
patent: 5108758 (1992-04-01), Allwood et al.
S. Candy et al., "A double-blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease," Gastroenterology, 106, A659 (Apr. 1994).
R. Caprilli et al., "A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary Report," Dig. Dis., 20, 115-120 (1975).
K. Ewe et al., "Azathioprine combined with prednisolone or monotherapy with prednisone in active Crohn's disease," Gastroenterology, 105, 367-372 (Aug. 1993).
D.P. Jewell et al., "Azathioprine in ulcerative colitis: final report on controlled therapeutic trial," Br. Med. J., 4, 627-639 (1974).
A.P. Kirk et al., "Controlled trial of azathioprine in chronic ulcerative colitis," Br. Med. J., 284, 1291-1292 (1982).
J.L. Rosenberg et al., "A controlled trial of azathioprine in the management of chronic ulcerative colitis," Gastroenterology, 69, 96-99 (1975).
L.R. Sutherland, "Topical treatment of ulcerative colitis," Med. Clin. North Am., 74, 119-131 (Jan. 1990).
Y. Takeichi et al., "Improvement of aqueous solubility and rectal absorption of 6-mercaptopurine by addition of sodium benzoate," Biol. Pharm. Bull., 17, 1391-1394 (Oct. 1994).
P.C. Adamson et al., "A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors", Cancer Chemother. Pharmacol., 26, 343-344 (1990).
C.A.S. Arndt et al., "Bioavailability of low-dose vs high-dose 6-mercaptopurine", Clin. Pharmocol. Ther., 43, 588-591 (May 1988).
G.L.C. Chan et al., "Azathioprine Metabolism: Pharmacokinetics of 6-Mercaptopurine, 6-Thiouric Acid and 6-Thioguanine Mucleotides in Renal Transplant Patients", J. Clin. Pharmacol., 30, 358-363 (1990).
W.R. Connell et al., "Bone Marrow Toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience", Gut, 34, 1081-1085 (1993).
A.B. Hawthorne et al., "Randomised controlled trial of azathioprine withdrawal in ulcerated colitis", Brit. J. Med., 305, 20-22 (1992).
M. Klein et al., "Treatment of Crohn's Disease with Azathioprine: A Controlled Evaulation", Gastroenterology, 66, 916-922 (1974).
B.I. Korelitz et al., "Shortcomings of the National Crohn's Disease Study: The Exclusion of Azathioprine Without Adequate Trial", Gastroenterology, 80, 193-194 (1981).
B.I. Korelitz et al., "Favorable Effect of 6-Mercaptopurine on Fistulae of Crohn's Disease", Digestive Diseases and Sciences, 30, 58-64 (Jan. 985).
L. Lennard et al., "Azathioprine metabolism in kidney transplant recipients", Br. J. Clin. Pharmac., 18, 693-700 (1984).
J. Markowitz et al., "Long-Term 6-Mercaptopurine Treatment in Adolescents with Crohn's Disease", Gastroenterology, 99, 1347-1351 (1990).
M. Nyman et al., "Long-Term Immunosuppressive Treatment in Crohn's Disease", Canadian J. Gastroenterology, 20, 1197-1203 (Nov. 10, 1985).
B. Odlind et al., "Serum Azathioprine and 6-Mercaptopurine Levels and Immunosuppressive Activity after Azathioprine in Uremic Patients", Int. J. Immunopharmac., 8, 1-11 (1986).
D.P. O'Donoghue et al., "Double-Blind Withdrawal Trial of Azathioprine as Maintenance Treatment for Crohn's Disease", The Lancet, 955-957 (Nov. 4, 1978).
J. Perrault et al., "6-Mercaptopurine Therapy in Selected Cases of Corticosteroid-Dependent Crohn's Disease", Mayo Clin. Proc., 66, 480-484 (1991).
D.H. Present et al., "Treatment of Crohn's Disease with 6-Mercaptopurine", N. Eng. J. Med., 302, 981-987 (May 1, 1980).
D.H. Present et al., "6-Mercaptopurine in the Management of inflammatory Bowel Disease: Short-and Long-Term Toxicity", Annals of Internal Medicine, 111, 641-649 (Oct. 15, 1989).
J. Rhodes et al., "Controlled Trial of Azathioprine in Crohn's Disease", The Lancet, 1273-1276 (Dec. 11, 1971).
J.L. Rosenberg et al., "A Controlled Trial of Azathioprine in Crohn's Disease", Digestive Diseases, 20, 721-726 (Aug. 1975).
J.W. Singleton, "Azathioprine Has a Very Limited Role in the Treatment of Crohn's Disease", Digestive Diseases and Sciences, 26, 368-371 (Apr. 1981).
R.W. Summers et al., "National Cooperative Crohn's Disease Study: Results of Drug Treatment", Gastroenterology, 77, 847-869 (1979).
M. Verhave et al., "Azathioprine in the treatment of children with inflammatory bowel disease", J. Pediatrics, 117, 809-814 (Nov. 1990).
J.M.T. Willoughby et al., "Controlled Trial of Azathioprine in Crohn's Disease", The Lancet, 944-946 (Oct. 30, 1971).
W.P. Wilson et al., "Azathioprine" in Analytical Profiles of Drug Substances, vol. 10; K. Florey, Ed.; Academic Press: New York; pp. 30-53; 1981.
S. Zimm et al., "Phase I and Clinical Pharmacological Study of Mercaptopurine Administered as a Prolonged Intravenous Infusion", Cancer Research, 45, 1869-1873 (Apr. 1985).
S. Zimm et al., "Variable Bioavailability of Oral Mercaptopurine", N. Eng. J. Med., 308, 1005-1009 (1983).
Abstract of Japanese Patent Application No. 62 072618, issued Apr. 3, 1987, (Takada) from Database WPI, Derwent Publications Ltd., London.
Jarvis William R. A.
Mayo Foundation for Medical Education and Research
LandOfFree
Use of topical azathioprine to treat inflammatory bowel disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of topical azathioprine to treat inflammatory bowel disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of topical azathioprine to treat inflammatory bowel disorder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2107367